## Table 2 |
|||

Model parameters and their prior distributions |
|||

Parameter description |
Symbol |
Prior |
Source |

Per-partnership probability of transmission from female to male used to calculate
the force of infection λ. |
β_{m} |
U(0.10-1.00) | [25] |

Per-partnership probability of transmission from male to female used to calculate
the force of infection λ. |
β_{f} |
U(0.10-1.00) | [25] |

Average duration of infection for males | T_{in,m} |
U(0.60,1.70) | [26,27] |

Average duration of infection for females | T_{in,f} |
U(0.75,1.50) | [28-30] |

Average rate of loss of immunity for males; defined as 1/T_{im,m} i.e. the inverse of the average duration of natural immunity for males |
r_{li,m} |
U(0.01,0.33) (SIRS_{1}, SIRS_{2}); U(0.01,1.0) (SIRS_{3}, SIRS_{4}); |
[31] (SIRS_{1}, SIRS_{2}); Not available (SIRS_{3}, SIRS_{4}); |

Average rate of loss of immunity for females; defined as 1/Tim,f i.e. the inverse of the of natural immunity for females | r_{li,f} |
U(0.01,0.33) (SIRS_{1}, SIRS_{2}); U(0.01,1.0) (SIRS_{3}, SIRS_{4}); |
[31] (SIRS_{1}, SIRS_{2}); Not available (SIRS_{3}, SIRS_{4}); |

Probability of seroconversion for males | p_{m} |
U(0.01,0.30) | [15] |

Probability of seroconversion for females | p_{f} |
U(0.40,0.70) | [32] |

Average rate of seroreversion for males | r_{sr,m} |
U(0.01,0.10) | [33] |

Average rate of seroreversion for females | r_{sr,f} |
U(0.10,1.00) | [18,32,34] |

Average degree of immunity for seropositive males | s_{m} |
U(0.00,1.00) | Not available |

Average degree of immunity for seropositive females | s_{f} |
U(0.10,1.00) | [35-37] |

Average time to seroconversion for males (a proportion of T_{in,m}) |
T_{sc,m} |
U(0.50,0.95) | [15] |

Average time to conversion for females (a proportion of T_{in,f}) |
T_{sc,f} |
U(0.50,0.95) | [32,33] |

Degree of assortativity by age group | ε_{a} |
U(0.10,0.90) | Not available |

Degree of assortativity by sexual activity group | ε_{r} |
U(0.10,0.90) | Not available |

All durations are in years, and all rates are per capita annual rates.

Korostil * et al.*

Korostil * et al.* *BMC Infectious Diseases* 2013 **13**:83 doi:10.1186/1471-2334-13-83